Contributions
Abstract: P295
Type: Poster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Background: Neuromyelitis optica spectrum disorders (NMOSD) are responsible for long-term disability in adults and children. Though much has recently been learned about its pathogenesis, population-based studies regarding the epidemiology of NMOSD are scarce, have shown variable prevalence rates and have been conducted before the implementation of the most recently proposed 2015 diagnostic criteria.
Aim: To estimate the incidence, prevalence and clinical features of NMOSD in a Southern European white Caucasian population (Catalonia, Spain), based on the 2015 NMOSD diagnostic criteria.
Methods: This was a population-based multicenter retrospective study. Between 2006 and 2015, adults and children with a first-ever diagnosis of NMOSD according to the 2015 criteria were identified using multiple sources of data: aquaporin-4 antibody (AQP4-IgG) testing laboratory registry, identification of all those residents in Catalonia who during the study time period appeared in the Catalan Healthy Surveillance System with a diagnosis of NMOSD (WHO ICD-9 code: 341.0) and contacting 41 hospitals throughout Catalonia. Incidence rate was calculated for the period 01/01/2006 to 01/01/2016 dividing the number of patients with onset date of NMOSD in this period by the total number of person-year at risk and prevalence rate was calculated for the date 01/01/2016. Serum samples were tested for AQP4-IgG by cell-based assay (CBA), immunohistochemistry or ELISA. Additionally, presence of antibodies to MOG (MOG-IgG) was investigated by CBA.
Results: Seventy-four patients were identified in a population of 7,522,596 inhabitants. Most cases were white Caucasian (81%), and female (76%) with mean age at onset 40.6 years (range 10-76). Fifty-four (73%) patients were positive for AQP4-IgG and 20 (27%), seronegative. Nine out of fifteen (60%) seronegative patients were positive for MOG-IgG. The incidence rate of NMOSD in the Catalonian population was estimated to be 0.63 cases per 106 person-years and the prevalence 0.89 cases per 105 inhabitants.
Conclusions: This is the first population-based epidemiological study applying the 2015 NMOSD criteria. Prevalence and incidence rates confirm NMOSD as a rare disease in a predominant white Caucasian population.
Disclosure: Funding: This work was funded by a grant from La Marató de TV3 (20141830). MS receives funding from the Generalitat de Catalunya (SLT002/16/00354). TA has received funding from Instituto Carlos III, Madrid, Spain (CM14/00081 and CV15/00021). AS receives funding from the Spanish Government (PI15/00587, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02).
MS received speaker honoraria from Genzyme and Novartis.
SL received speaker honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck, and research support from a Juan Rodes grant from the Instituto de Salud Carlos III (JR14/00016) and the Spanish Government (PI15/00587).
GA has received compensation for consulting services from Biogen-Idec, research support from Novartis, and speaking honoraria from Sanofi-Aventis.
SO-R has received compensation for consulting services from Biogen-Idec and Genzyme, and research support from Novartis.
JS-G has received compensation for participating on Advisory Boards, speaking honoraria and travel expenses for scientific meetings, consulting services or research support from Novartis, Biogen, Serono Symposia International Foundation, Merck, Almirall, and Genzyme.
LR-P received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
SM-Y has received honoraria compensation for participating in AdvisoryBoards, acting as consultant and for speaking activities from Biogen idec, Teva, Sanofi-Aventis, Merck Serono, Novartis and Farmacéutica Bayer Schering.
NS-V receives funding from the Spanish Government (Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER, FI16/00251), and a Predoctoral Grant for Health Research.
RR had received speaker honoraria from Bayer, Biogen and Novartis.
LR-T has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.
CR received travel funding from Biogen and Novartis and received research support from Biogen, Genzyme, Novartis and Almirall.
EM has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Merck-Serono, Genzyme and Almirall.
LB has received speaking honoraria from Biogen Idec, Novartis, Merck-Serono, Genzyme and Almirall.
MAM-M has received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering Pharma.
MT has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merck-Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Novartis, Almirall, Genzyme, and Roche.
YB received speaking honoraria from Biogen, Novartis and Genzyme.
XM has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Actelion, Amirall, Bayer, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.
AS received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA and Novartis.
MA, DE, TA, JS, AE, SP, RP, LG, NO, MH, AC, EV and FG report no disclosures.
Abstract: P295
Type: Poster
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Background: Neuromyelitis optica spectrum disorders (NMOSD) are responsible for long-term disability in adults and children. Though much has recently been learned about its pathogenesis, population-based studies regarding the epidemiology of NMOSD are scarce, have shown variable prevalence rates and have been conducted before the implementation of the most recently proposed 2015 diagnostic criteria.
Aim: To estimate the incidence, prevalence and clinical features of NMOSD in a Southern European white Caucasian population (Catalonia, Spain), based on the 2015 NMOSD diagnostic criteria.
Methods: This was a population-based multicenter retrospective study. Between 2006 and 2015, adults and children with a first-ever diagnosis of NMOSD according to the 2015 criteria were identified using multiple sources of data: aquaporin-4 antibody (AQP4-IgG) testing laboratory registry, identification of all those residents in Catalonia who during the study time period appeared in the Catalan Healthy Surveillance System with a diagnosis of NMOSD (WHO ICD-9 code: 341.0) and contacting 41 hospitals throughout Catalonia. Incidence rate was calculated for the period 01/01/2006 to 01/01/2016 dividing the number of patients with onset date of NMOSD in this period by the total number of person-year at risk and prevalence rate was calculated for the date 01/01/2016. Serum samples were tested for AQP4-IgG by cell-based assay (CBA), immunohistochemistry or ELISA. Additionally, presence of antibodies to MOG (MOG-IgG) was investigated by CBA.
Results: Seventy-four patients were identified in a population of 7,522,596 inhabitants. Most cases were white Caucasian (81%), and female (76%) with mean age at onset 40.6 years (range 10-76). Fifty-four (73%) patients were positive for AQP4-IgG and 20 (27%), seronegative. Nine out of fifteen (60%) seronegative patients were positive for MOG-IgG. The incidence rate of NMOSD in the Catalonian population was estimated to be 0.63 cases per 106 person-years and the prevalence 0.89 cases per 105 inhabitants.
Conclusions: This is the first population-based epidemiological study applying the 2015 NMOSD criteria. Prevalence and incidence rates confirm NMOSD as a rare disease in a predominant white Caucasian population.
Disclosure: Funding: This work was funded by a grant from La Marató de TV3 (20141830). MS receives funding from the Generalitat de Catalunya (SLT002/16/00354). TA has received funding from Instituto Carlos III, Madrid, Spain (CM14/00081 and CV15/00021). AS receives funding from the Spanish Government (PI15/00587, RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02).
MS received speaker honoraria from Genzyme and Novartis.
SL received speaker honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck, and research support from a Juan Rodes grant from the Instituto de Salud Carlos III (JR14/00016) and the Spanish Government (PI15/00587).
GA has received compensation for consulting services from Biogen-Idec, research support from Novartis, and speaking honoraria from Sanofi-Aventis.
SO-R has received compensation for consulting services from Biogen-Idec and Genzyme, and research support from Novartis.
JS-G has received compensation for participating on Advisory Boards, speaking honoraria and travel expenses for scientific meetings, consulting services or research support from Novartis, Biogen, Serono Symposia International Foundation, Merck, Almirall, and Genzyme.
LR-P received research support, funding for travel and congress expenses and honoraria from speaking engagements and scientific advisory board from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono.
SM-Y has received honoraria compensation for participating in AdvisoryBoards, acting as consultant and for speaking activities from Biogen idec, Teva, Sanofi-Aventis, Merck Serono, Novartis and Farmacéutica Bayer Schering.
NS-V receives funding from the Spanish Government (Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER, FI16/00251), and a Predoctoral Grant for Health Research.
RR had received speaker honoraria from Bayer, Biogen and Novartis.
LR-T has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd and Almirall.
CR received travel funding from Biogen and Novartis and received research support from Biogen, Genzyme, Novartis and Almirall.
EM has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Merck-Serono, Genzyme and Almirall.
LB has received speaking honoraria from Biogen Idec, Novartis, Merck-Serono, Genzyme and Almirall.
MAM-M has received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering Pharma.
MT has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merck-Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Novartis, Almirall, Genzyme, and Roche.
YB received speaking honoraria from Biogen, Novartis and Genzyme.
XM has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Actelion, Amirall, Bayer, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.
AS received compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA and Novartis.
MA, DE, TA, JS, AE, SP, RP, LG, NO, MH, AC, EV and FG report no disclosures.